Patients Affected by Vitiligo and Autoimmune Diseases Do Not Show Antibodies Interfering with the Activity of the Melanocortin 1 Receptor

Overview

Journal J Endocrinol Invest

Publisher Springer

Specialty Endocrinology

Date 2010 Mar 25

PMID 20332705

Authors

P Agretti

G De Marco

D Sansone

C Betterle

G Coco

A Dimida

E Ferrarini

A Pinchera

P Vitti

M Tonacchera

Affiliations

Soon will be listed here.

Abstract

Background: Vitiligo is an acquired depigmenting disorder characterized by the loss of melanocytes from the epidermis with the development of white patches in various distribution. The pathogenesis of vitiligo is still unknown, but the association with autoimmune disorders and organ specific autoantibodies, supports the hypothesis of an autoimmune pathogenesis.

Aim: The aim of the present study was to investigate if autoantibodies present in sera of patients affected by vitiligo may be able to interfere with the activity of the αMSH on the melanocortin 1 receptor (MC1R). MATERIALS/ SUBJECTS AND METHODS: IgG from the sera of 41 patients with vitiligo associated or not with thyroid autoimmune diseases or other autoimmune pathologies were incubated with HBL20 cells (human malignant melanocytes expressing the MC1R) in the presence of a sub-maximal dose of αMSH. A normal IgG range was determined by using IgG extracted from 30 control sera of normal subjects.

Results: None of the IgG from vitiligo patients was able to inhibit αMSH-stimulated cAMP production in HBL20 cells.

Conclusions: Autoantibodies against MC1R are rare or absent in sera of vitiligo patients.

References

Majumder P, Das S, Li C . A genetical model for vitiligo. Am J Hum Genet. 1988; 43(2):119-25. PMC: 1715367. View

Ongenae K, van Geel N, Naeyaert J . Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res. 2003; 16(2):90-100. DOI: 10.1034/j.1600-0749.2003.00023.x. View

Betterle C, Mirakian R, Doniach D, Bottazzo G, Riley W, Maclaren N . Antibodies to melanocytes in vitiligo. Lancet. 1984; 1(8369):159. DOI: 10.1016/s0140-6736(84)90084-9. View

Goudie B, Wilkieson C, Goudie R . A family study of vitiligo patterns. Scott Med J. 1983; 28(4):338-42. DOI: 10.1177/003693308302800405. View

Blecher M . Receptors, antibodies, and disease. Clin Chem. 1984; 30(7):1137-56. View

Lepe V, Moncada B, Castanedo-Cazares J, Torres-Alvarez M, Ortiz C, Torres-Rubalcava A . A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol. 2003; 139(5):581-5. DOI: 10.1001/archderm.139.5.581. View

Fishman P, Azizi E, Shoenfeld Y, Sredni B, Yecheskel G, Ferrone S . Vitiligo autoantibodies are effective against melanoma. Cancer. 1993; 72(8):2365-9. DOI: 10.1002/1097-0142(19931015)72:8<2365::aid-cncr2820720812>3.0.co;2-g. View

Iacovelli P, Sinagra J, Paro Vidolin A, Marenda S, Capitanio B, Leone G . Relevance of thyroiditis and of other autoimmune diseases in children with vitiligo. Dermatology. 2004; 210(1):26-30. DOI: 10.1159/000081479. View

Kemp E, Waterman E, Weetman A . Autoimmune aspects of vitiligo. Autoimmunity. 2001; 34(1):65-77. DOI: 10.3109/08916930108994127. View

10.

Cui J, Arita Y, Bystryn J . Characterization of vitiligo antigens. Pigment Cell Res. 1995; 8(1):53-9. DOI: 10.1111/j.1600-0749.1995.tb00774.x. View

11.

Gilhar A, Zelickson B, Ulman Y, Etzioni A . In vivo destruction of melanocytes by the IgG fraction of serum from patients with vitiligo. J Invest Dermatol. 1995; 105(5):683-6. DOI: 10.1111/1523-1747.ep12324456. View

12.

Cui J, Harning R, Henn M, Bystryn J . Identification of pigment cell antigens defined by vitiligo antibodies. J Invest Dermatol. 1992; 98(2):162-5. DOI: 10.1111/1523-1747.ep12555773. View

13.

Schwartz R, Janniger C . Vitiligo. Cutis. 1997; 60(5):239-44. View

14.

Okamoto T, Irie R, Fujii S, Huang S, Nizze A, Morton D . Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy. J Invest Dermatol. 1998; 111(6):1034-9. DOI: 10.1046/j.1523-1747.1998.00411.x. View

15.

Lorini R, Orecchia G, Martinetti M, Dugoujon J, Cuccia M . Autoimmunity in vitiligo: relationship with HLA, Gm and Km polymorphisms. Autoimmunity. 1992; 11(4):255-60. DOI: 10.3109/08916939209035163. View

16.

Bystryn J . Serum antibodies in vitiligo patients. Clin Dermatol. 1989; 7(2):136-45. DOI: 10.1016/0738-081x(89)90063-1. View

17.

Betterle C, Del Prete G, Peserico A, Bersani G, Caracciolo F, Trisotto A . Autoantibodies in vitiligo. Arch Dermatol. 1976; 112(9):1328. View

18.

Siegrist W, Solca F, Stutz S, GIUFFRE L, Carrel S, Girard J . Characterization of receptors for alpha-melanocyte-stimulating hormone on human melanoma cells. Cancer Res. 1989; 49(22):6352-8. View

19.

Gottumukkala R, Waterman E, Herd L, Gawkrodger D, Watson P, Weetman A . Autoantibodies in vitiligo patients recognize multiple domains of the melanin-concentrating hormone receptor. J Invest Dermatol. 2003; 121(4):765-70. DOI: 10.1046/j.1523-1747.2003.12494.x. View

20.

Kemp E, Gawkrodger D, MacNeil S, Watson P, Weetman A . Detection of tyrosinase autoantibodies in patients with vitiligo using 35S-labeled recombinant human tyrosinase in a radioimmunoassay. J Invest Dermatol. 1997; 109(1):69-73. DOI: 10.1111/1523-1747.ep12276556. View